Ensartinib is a medicine being studied to see if it can help children with certain tough cancers, like solid tumors, non-Hodgkin lymphoma, and histiocytic disorders. These cancers have changes in their genes, called ALK or ROS1 genomic alterations, which help the cancer grow. Ensartinib might stop cancer cells from growing by blocking enzymes that these cells need.
In this study, children will take ensartinib by mouth every day for up to 2 years, as long as it keeps working and they can handle it. During the study, doctors will do different tests, like x-rays and blood tests, to see how the cancer is doing and how the child is responding to the treatment.
- The study lasts up to 2 years with daily medication.
- Regular tests and scans are part of the study.
- Children must be between 1 and 21 years old to join.
It's important for children and their parents to talk to their doctors to understand the possible benefits and risks before deciding to join this study.